A massive restructuring of WHO’s 2020-2021 budget should see a shift away from siloed disease control programmes to a more integrated approach, focused on building health systems and strengthening country operations. These were the key strategic features of the proposed budget of US$ 4.785 billion, reviewed by WHO’s Executive Board in a lengthy session today. Continue reading ->
When historians look back, will this year mark a turning point in global health? Certainly some of the big issues on the agenda in 2019 might suggest that we are at a crossroads. We can expect to see an intensification of the push for universal health coverage (UHC), culminating with a first-ever high-level United Nations meeting, and a shift away from disease-specific interventions towards more integrated approaches. Health Policy Watch spoke with a range of leading global health policy experts from the World Health Organization (WHO), NGOs, industry and foundations to get their take on the top issues, and here is what they said to watch for in 2019 in five priority areas. Continue reading ->
According to the World Health Organization, noncommunicable diseases (NCDs) - or chronic diseases - including cancer, cardiovascular diseases, and diabetes, kill 41 million people each year and are on the rise in developing countries. This week, the WHO held the first general meeting of its mechanism aiming at facilitating prevention and control of NCD diseases. The numerous speakers shared local, regional, and international experiences in implementing measures. Separately, WHO announced the launch of a new collaborative platform for NCDs. Continue reading ->
The chief of the Framework Convention on Tobacco Control Secretariat, Vera Luiza da Costa e Silva, told delegates from its 181 member states attending a Conference of the Parties meeting in Geneva (1-6 October) many governments have advanced tobacco control actions, but also noted some are lagging behind and warned that with astronomical budgets, the tobacco industry "continues their furious efforts" to undermine the implementation of the treaty. Continue reading ->
Brazil is frequently pointed to as one of the countries in which fewer pharmaceutical patents are granted. The fact that there is a low number of patents granted could lead to the conclusion that medicines can be bought under competition and that the prices would be low. However, many medicines in Brazil are bought exclusively from one producer and usually at high prices. The situation of few granted patents, but many purchases under exclusivity due to absence of competition (which can lead to higher prices), is what we are calling the ‘patent paradox in Brazil’. In the absence of granted patents, what are the factors that lead to the situation of no competition and high prices in Brazil? This is the question that we, at the accessibsa: Innovation & Access to Medicines in India, Brazil & South Africa, aim to answer with a study currently being conducted at the Department of Medicines Policy and Pharmaceutical Services (NAF) of the Sergio Arouca National School of Public Health – ENSP/Fiocruz. Continue reading ->